140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Title:
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Author:
Felip, E. Spigel, D.R. Juan Vidal, O.J. Beck, J.T. Aguado de la Rosa, C. Johnson, D.H. Spath-Schwalbe, E. Reinacher-Schick, A. Rodriguez Abreu, D. Altan, M. Reinmuth, N. Edelman, M.J. Reck, M. Zhao, Q. Banerjee, S. Chaudhry, S. Chien, D. Tagliaferri, M.A. Zalevsky, J. Ganti, A.